Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute Kidney Injury | 27 | 2024 | 1972 | 6.070 |
Why?
|
Hearing Loss | 4 | 2020 | 765 | 1.640 |
Why?
|
Renal Replacement Therapy | 5 | 2023 | 257 | 1.490 |
Why?
|
Ascites | 2 | 2020 | 344 | 1.260 |
Why?
|
Critical Illness | 21 | 2023 | 2670 | 1.250 |
Why?
|
Hyponatremia | 2 | 2020 | 298 | 1.180 |
Why?
|
Renal Insufficiency, Chronic | 6 | 2024 | 2208 | 1.160 |
Why?
|
Cisplatin | 5 | 2024 | 1662 | 1.130 |
Why?
|
Intensive Care Units | 14 | 2022 | 3679 | 0.820 |
Why?
|
Fanconi Syndrome | 1 | 2022 | 35 | 0.820 |
Why?
|
Thrombotic Microangiopathies | 1 | 2023 | 132 | 0.820 |
Why?
|
Paraproteinemias | 1 | 2024 | 246 | 0.780 |
Why?
|
Diphenhydramine | 1 | 2021 | 63 | 0.770 |
Why?
|
Water-Electrolyte Balance | 2 | 2020 | 346 | 0.720 |
Why?
|
Neoplasms | 8 | 2024 | 21683 | 0.700 |
Why?
|
Hospital Mortality | 14 | 2022 | 5317 | 0.690 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2020 | 113 | 0.670 |
Why?
|
Respiratory Insufficiency | 3 | 2021 | 1199 | 0.640 |
Why?
|
Catheters, Indwelling | 1 | 2020 | 426 | 0.620 |
Why?
|
Carbonic Anhydrase Inhibitors | 1 | 2017 | 95 | 0.590 |
Why?
|
Mesothelioma | 1 | 2023 | 818 | 0.590 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2019 | 357 | 0.580 |
Why?
|
Electrolytes | 1 | 2017 | 282 | 0.570 |
Why?
|
Fatigue | 1 | 2023 | 1531 | 0.540 |
Why?
|
Hyperammonemia | 1 | 2016 | 76 | 0.520 |
Why?
|
Acidosis | 1 | 2017 | 270 | 0.520 |
Why?
|
Fructose | 1 | 2017 | 288 | 0.520 |
Why?
|
Ammonia | 1 | 2016 | 239 | 0.520 |
Why?
|
Immunotherapy, Adoptive | 3 | 2022 | 1270 | 0.520 |
Why?
|
Drainage | 1 | 2020 | 1142 | 0.500 |
Why?
|
Bone Density Conservation Agents | 1 | 2022 | 773 | 0.490 |
Why?
|
Duffy Blood-Group System | 1 | 2014 | 58 | 0.490 |
Why?
|
Sodium | 1 | 2020 | 1623 | 0.480 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 1378 | 0.460 |
Why?
|
Blood Group Incompatibility | 1 | 2014 | 146 | 0.460 |
Why?
|
Creatinine | 4 | 2024 | 1919 | 0.460 |
Why?
|
Anemia, Hemolytic | 1 | 2014 | 168 | 0.460 |
Why?
|
Kidney Diseases | 1 | 2024 | 2149 | 0.430 |
Why?
|
Antineoplastic Agents | 4 | 2023 | 13695 | 0.420 |
Why?
|
Humans | 78 | 2024 | 744343 | 0.390 |
Why?
|
Cohort Studies | 17 | 2024 | 40561 | 0.390 |
Why?
|
Glomerular Filtration Rate | 5 | 2023 | 2170 | 0.380 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2023 | 5442 | 0.380 |
Why?
|
Kidney Neoplasms | 3 | 2022 | 4262 | 0.380 |
Why?
|
Echocardiography | 1 | 2023 | 5102 | 0.370 |
Why?
|
Carcinoma, Renal Cell | 3 | 2022 | 3143 | 0.370 |
Why?
|
Graft vs Host Disease | 1 | 2023 | 2957 | 0.370 |
Why?
|
Prone Position | 2 | 2021 | 194 | 0.360 |
Why?
|
Renal Dialysis | 3 | 2021 | 1786 | 0.360 |
Why?
|
Erythrocyte Transfusion | 1 | 2014 | 565 | 0.350 |
Why?
|
Middle Aged | 40 | 2024 | 213383 | 0.340 |
Why?
|
Internal Medicine | 1 | 2016 | 1009 | 0.340 |
Why?
|
Interleukin-6 | 1 | 2019 | 3200 | 0.340 |
Why?
|
Carboplatin | 2 | 2023 | 801 | 0.340 |
Why?
|
Health Services Needs and Demand | 1 | 2017 | 1411 | 0.340 |
Why?
|
Kidney | 7 | 2024 | 7186 | 0.330 |
Why?
|
Immunotherapy | 2 | 2021 | 4445 | 0.330 |
Why?
|
Teaching | 1 | 2016 | 1174 | 0.330 |
Why?
|
Critical Care | 2 | 2021 | 2647 | 0.330 |
Why?
|
Adult | 33 | 2024 | 214055 | 0.320 |
Why?
|
C-Reactive Protein | 2 | 2020 | 3778 | 0.320 |
Why?
|
Patient Positioning | 2 | 2021 | 324 | 0.320 |
Why?
|
Aged | 32 | 2024 | 163280 | 0.310 |
Why?
|
Fellowships and Scholarships | 1 | 2016 | 1076 | 0.310 |
Why?
|
ABO Blood-Group System | 2 | 2020 | 367 | 0.300 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3523 | 0.300 |
Why?
|
Risk Factors | 18 | 2024 | 72290 | 0.290 |
Why?
|
Adrenal Cortex Hormones | 3 | 2022 | 1855 | 0.280 |
Why?
|
Female | 42 | 2023 | 380194 | 0.280 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4838 | 0.280 |
Why?
|
Incidence | 7 | 2021 | 20947 | 0.270 |
Why?
|
Multiple Myeloma | 1 | 2024 | 5181 | 0.270 |
Why?
|
Receptors, Cell Surface | 1 | 2014 | 2866 | 0.250 |
Why?
|
Kidney Failure, Chronic | 1 | 2017 | 2538 | 0.240 |
Why?
|
Nephritis, Interstitial | 2 | 2023 | 156 | 0.240 |
Why?
|
Retrospective Studies | 22 | 2024 | 77449 | 0.240 |
Why?
|
Male | 40 | 2023 | 350118 | 0.230 |
Why?
|
Ribose | 1 | 2023 | 68 | 0.230 |
Why?
|
Inflammation | 2 | 2021 | 10638 | 0.220 |
Why?
|
Receptors, Interleukin-6 | 2 | 2021 | 224 | 0.220 |
Why?
|
Paraneoplastic Syndromes | 1 | 2024 | 151 | 0.210 |
Why?
|
Communication | 1 | 2016 | 3749 | 0.210 |
Why?
|
Fibrin Fibrinogen Degradation Products | 2 | 2021 | 426 | 0.210 |
Why?
|
Respiration, Artificial | 3 | 2023 | 2569 | 0.200 |
Why?
|
Dyspnea | 2 | 2023 | 1303 | 0.200 |
Why?
|
Bradycardia | 1 | 2023 | 307 | 0.200 |
Why?
|
Lung Neoplasms | 2 | 2024 | 13102 | 0.200 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2023 | 440 | 0.200 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12354 | 0.200 |
Why?
|
Hyperkalemia | 1 | 2023 | 218 | 0.190 |
Why?
|
Ifosfamide | 1 | 2021 | 228 | 0.190 |
Why?
|
Bicarbonates | 1 | 2022 | 313 | 0.190 |
Why?
|
United States | 17 | 2022 | 69872 | 0.190 |
Why?
|
Organ Transplantation | 2 | 2021 | 1139 | 0.180 |
Why?
|
Magnesium | 1 | 2023 | 813 | 0.180 |
Why?
|
Nephrology | 1 | 2024 | 263 | 0.180 |
Why?
|
Health Services Accessibility | 1 | 2017 | 5137 | 0.180 |
Why?
|
Pandemics | 6 | 2021 | 8388 | 0.170 |
Why?
|
Wisconsin | 1 | 2019 | 124 | 0.170 |
Why?
|
Comorbidity | 7 | 2021 | 10388 | 0.160 |
Why?
|
Plasmapheresis | 1 | 2019 | 211 | 0.160 |
Why?
|
Hearing Tests | 1 | 2019 | 122 | 0.160 |
Why?
|
Kidney Tubules | 1 | 2020 | 488 | 0.160 |
Why?
|
Hospitalization | 4 | 2021 | 10262 | 0.150 |
Why?
|
Kidney Glomerulus | 1 | 2020 | 697 | 0.150 |
Why?
|
Vomiting | 1 | 2021 | 636 | 0.150 |
Why?
|
Blood Coagulation Disorders | 1 | 2021 | 337 | 0.150 |
Why?
|
Neuroma, Acoustic | 1 | 2021 | 451 | 0.150 |
Why?
|
Standard of Care | 1 | 2021 | 564 | 0.150 |
Why?
|
Patients | 1 | 2024 | 900 | 0.150 |
Why?
|
Anticoagulants | 3 | 2021 | 4599 | 0.150 |
Why?
|
Glomerulosclerosis, Focal Segmental | 1 | 2020 | 357 | 0.150 |
Why?
|
Thrombosis | 2 | 2021 | 2968 | 0.140 |
Why?
|
Internship and Residency | 1 | 2016 | 5788 | 0.140 |
Why?
|
Transplantation Conditioning | 1 | 2023 | 1598 | 0.140 |
Why?
|
Arteriosclerosis | 1 | 2020 | 1092 | 0.140 |
Why?
|
Paclitaxel | 1 | 2023 | 1708 | 0.130 |
Why?
|
Survival Rate | 5 | 2021 | 12788 | 0.130 |
Why?
|
Amino Acids | 1 | 2022 | 1736 | 0.130 |
Why?
|
Severity of Illness Index | 4 | 2021 | 15540 | 0.130 |
Why?
|
Aged, 80 and over | 8 | 2021 | 57776 | 0.130 |
Why?
|
Bayes Theorem | 1 | 2023 | 2309 | 0.130 |
Why?
|
Pleural Neoplasms | 1 | 2020 | 607 | 0.130 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2023 | 2540 | 0.130 |
Why?
|
Tissue Plasminogen Activator | 1 | 2021 | 1261 | 0.130 |
Why?
|
Living Donors | 1 | 2019 | 620 | 0.130 |
Why?
|
Nephrectomy | 1 | 2020 | 1050 | 0.120 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2018 | 11725 | 0.120 |
Why?
|
Desensitization, Immunologic | 1 | 2019 | 483 | 0.120 |
Why?
|
Blood Coagulation | 1 | 2020 | 1127 | 0.120 |
Why?
|
Cholecystitis | 1 | 2014 | 182 | 0.120 |
Why?
|
Premedication | 1 | 2014 | 258 | 0.120 |
Why?
|
Hematocrit | 1 | 2014 | 636 | 0.110 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3133 | 0.110 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3240 | 0.100 |
Why?
|
Hepatectomy | 1 | 2015 | 550 | 0.100 |
Why?
|
Birth Weight | 1 | 2020 | 2069 | 0.100 |
Why?
|
Hemorrhage | 2 | 2021 | 3461 | 0.100 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2014 | 367 | 0.100 |
Why?
|
Child Abuse, Sexual | 1 | 2013 | 383 | 0.090 |
Why?
|
Domestic Violence | 1 | 2012 | 176 | 0.090 |
Why?
|
Isoantibodies | 1 | 2014 | 679 | 0.090 |
Why?
|
Heart Arrest | 1 | 2020 | 1470 | 0.090 |
Why?
|
Pilot Projects | 1 | 2023 | 8324 | 0.090 |
Why?
|
Erythropoietin | 1 | 2014 | 726 | 0.090 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2021 | 1354 | 0.090 |
Why?
|
Contrast Media | 1 | 2023 | 5300 | 0.090 |
Why?
|
Adult Survivors of Child Abuse | 1 | 2013 | 260 | 0.090 |
Why?
|
Self Report | 1 | 2020 | 3558 | 0.090 |
Why?
|
Health Resources | 1 | 2015 | 911 | 0.090 |
Why?
|
Mortality | 1 | 2021 | 2864 | 0.090 |
Why?
|
Logistic Models | 2 | 2021 | 13408 | 0.080 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2021 | 2245 | 0.080 |
Why?
|
Drug Resistance | 1 | 2014 | 1609 | 0.080 |
Why?
|
Health Surveys | 1 | 2018 | 4037 | 0.080 |
Why?
|
Liver Transplantation | 1 | 2019 | 2119 | 0.080 |
Why?
|
Syndrome | 1 | 2014 | 3251 | 0.080 |
Why?
|
Diagnosis, Differential | 1 | 2023 | 12959 | 0.080 |
Why?
|
Young Adult | 5 | 2021 | 56430 | 0.080 |
Why?
|
Sex Factors | 1 | 2021 | 10397 | 0.080 |
Why?
|
Venous Thromboembolism | 2 | 2021 | 1671 | 0.080 |
Why?
|
Boston | 1 | 2020 | 9313 | 0.080 |
Why?
|
HIV Infections | 4 | 2015 | 16718 | 0.080 |
Why?
|
Hospitals | 1 | 2021 | 3952 | 0.070 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2017 | 1209 | 0.070 |
Why?
|
Adolescent | 6 | 2021 | 85781 | 0.070 |
Why?
|
Brain Diseases | 1 | 2016 | 1563 | 0.070 |
Why?
|
Pregnancy Complications | 1 | 2021 | 2861 | 0.070 |
Why?
|
Risk | 1 | 2018 | 9687 | 0.070 |
Why?
|
Hepatitis C, Chronic | 1 | 2014 | 1031 | 0.070 |
Why?
|
CD4 Lymphocyte Count | 1 | 2012 | 2559 | 0.070 |
Why?
|
Kidney Transplantation | 1 | 2020 | 4251 | 0.070 |
Why?
|
Homosexuality, Male | 1 | 2013 | 1240 | 0.070 |
Why?
|
Risk Assessment | 2 | 2024 | 23338 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 5221 | 0.060 |
Why?
|
Migraine Disorders | 1 | 2017 | 1620 | 0.060 |
Why?
|
Patient Compliance | 2 | 2013 | 2684 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 4034 | 0.060 |
Why?
|
Insurance, Health | 1 | 2017 | 2494 | 0.060 |
Why?
|
Prognosis | 3 | 2021 | 29063 | 0.060 |
Why?
|
Algorithms | 2 | 2021 | 13881 | 0.060 |
Why?
|
Acute Disease | 1 | 2014 | 7149 | 0.060 |
Why?
|
Age Factors | 1 | 2020 | 18370 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2016 | 3528 | 0.060 |
Why?
|
Viral Load | 1 | 2012 | 3299 | 0.060 |
Why?
|
Longitudinal Studies | 1 | 2019 | 13989 | 0.060 |
Why?
|
Baclofen | 1 | 2023 | 129 | 0.050 |
Why?
|
Digoxin | 1 | 2023 | 250 | 0.050 |
Why?
|
Cystatin C | 1 | 2023 | 250 | 0.050 |
Why?
|
Bilirubin | 1 | 2023 | 425 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11524 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2021 | 15295 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2020 | 5686 | 0.050 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39050 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 3923 | 0.050 |
Why?
|
Sclerosis | 1 | 2020 | 213 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 1 | 2023 | 20129 | 0.040 |
Why?
|
Vancomycin | 1 | 2023 | 501 | 0.040 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 3047 | 0.040 |
Why?
|
Obesity | 1 | 2021 | 12745 | 0.040 |
Why?
|
Thrombophilia | 1 | 2021 | 305 | 0.040 |
Why?
|
Troponin I | 1 | 2022 | 619 | 0.040 |
Why?
|
Kidney Function Tests | 1 | 2020 | 684 | 0.040 |
Why?
|
Prospective Studies | 2 | 2020 | 53288 | 0.040 |
Why?
|
Platelet Count | 1 | 2020 | 781 | 0.040 |
Why?
|
Liposarcoma | 1 | 2020 | 333 | 0.040 |
Why?
|
Hyperthermia, Induced | 1 | 2020 | 403 | 0.040 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15165 | 0.040 |
Why?
|
Leiomyosarcoma | 1 | 2020 | 477 | 0.030 |
Why?
|
Virginia | 1 | 2015 | 121 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2016 | 25625 | 0.030 |
Why?
|
Atrophy | 1 | 2020 | 1583 | 0.030 |
Why?
|
Interleukin-2 | 1 | 2023 | 1904 | 0.030 |
Why?
|
Tumor Burden | 1 | 2021 | 1915 | 0.030 |
Why?
|
Aftercare | 1 | 2021 | 866 | 0.030 |
Why?
|
Fibrosis | 1 | 2020 | 2029 | 0.030 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2020 | 808 | 0.030 |
Why?
|
Pneumonectomy | 1 | 2020 | 1094 | 0.030 |
Why?
|
Medical Oncology | 1 | 2024 | 2265 | 0.030 |
Why?
|
Unsafe Sex | 1 | 2013 | 220 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 2959 | 0.020 |
Why?
|
Morbidity | 1 | 2015 | 1769 | 0.020 |
Why?
|
Universities | 1 | 2015 | 956 | 0.020 |
Why?
|
India | 1 | 2015 | 2197 | 0.020 |
Why?
|
Patient Discharge | 1 | 2021 | 3313 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10252 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8642 | 0.020 |
Why?
|
Risk-Taking | 1 | 2013 | 986 | 0.020 |
Why?
|
Treatment Outcome | 3 | 2021 | 63114 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9849 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2020 | 25043 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11031 | 0.020 |
Why?
|
Length of Stay | 1 | 2020 | 6309 | 0.020 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2015 | 2232 | 0.020 |
Why?
|
Students | 1 | 2015 | 1654 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2012 | 1425 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7279 | 0.010 |
Why?
|
Forecasting | 1 | 2012 | 2951 | 0.010 |
Why?
|
Health Behavior | 1 | 2012 | 2636 | 0.010 |
Why?
|
Health Status | 1 | 2013 | 4034 | 0.010 |
Why?
|
Pregnancy | 1 | 2021 | 29144 | 0.010 |
Why?
|
Prevalence | 1 | 2013 | 15226 | 0.010 |
Why?
|
Time Factors | 1 | 2015 | 40075 | 0.010 |
Why?
|
Child | 1 | 2013 | 77709 | 0.000 |
Why?
|
Concepts
(244)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(119)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_